Patients with aaIPI 2-3 diffuse large B-cell lymphoma achieve 75% long-term survival following first-line rituximab-supplemented high-dose sequential chemotherapy and autograft: Final results of the prospective phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) trial.
Academic Article
Publication Date:
2007
Iris type:
1.1 Articolo in rivista
List of contributors:
Tarella, C; Zanni, M; Di Nicola, M; Patti, C; Castellino, C; Crocchiolo, R; Zoli, V; Caracciolo, D; Magni, M; Boccadoro, M; Ciceri, Fabio; Corradini, P; Gallamini, A; Majolino, I; Mirto, S; Gianni, Am
Published in: